Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 82

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 82
---
) per share of our common stock. Net tangible book value per share is equal to our total tangible assets less our mezzanine equity and total liabilities, divided by the number of shares of our outstanding common stock. Our pro forma net tangible book value (deficit) as of September 30, 2024, after Vivus Adjustments was $(8,972,238) or approximately $(0.90) per share. After giving further effect to (i) the sale of Units in this offering at the assumed public offering price of $0.2475 per share (the last reported sale price of our common stock on The Nasdaq Capital Market on February 13, 2025), and after deducting the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the cash exercise of the Series Warrants issued in this offering and assuming no Pre-Funded Warrants are issued in this offering, and (ii) the Pro Forma Adjustments, our pro forma as adjusted net tangible book value (deficit) per share after giving effect to this offering would have been $(1,987,238) or $(0.05) per share of common stock. This represents an immediate increase in as adjusted net tangible book value of $0.85 per share to our existing stockholders, and an immediate dilution of $0.30 per share to new investors purchasing securities in this offering at the assumed public offering price. The final public offering price will be determined between us, Dawson James and investors in the offering and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final public offering price. The following table illustrates this dilution on a per share basis:

| Assumed public offering price per share and accompanying Series Warrants                                                                                   
 Historical net tangible book value per share as of September 30, 2024                                                                                      | ​ | ​ 
 ​ | (0.68) | ​ | ​ |  0.25 | ​ |
|:-----------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|-------:|:--|:--|------:|:--|
| Pro forma decrease in net tangible book value per share attributable to the Vivus Adjustments                                                              | ​ | $ |  -0.22 | ​ | ​ |     ​ | ​ |
| Pro forma net tangible book value per share as of September 30, 2024, after giving effect to Viv